Archives of Medical Research
Volume 40, Issue 7 , Pages 571-575 , October 2009

High Prevalence of Coronary Heart Disease in Type 2 Diabetic Patients with Non-alcoholic Fatty Liver Disease

  • Hongyun Lu

      Affiliations

    • Department of Endocrinology, the Third Affiliated Hospital of Sun Yat-sen University, Guangdong, Guangzhou, China
    • Department of Endocrinology, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong, Zhuhai, China
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress reprint requests to: Dr. Hongyun Lu, Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen University, Guangdong, Guangzhou 510630, China; Phone: +86-756-2528741; FAX: +86-756-3316701
    • ,
  • Longyi Zeng

      Affiliations

    • Department of Endocrinology, the Third Affiliated Hospital of Sun Yat-sen University, Guangdong, Guangzhou, China
    • These authors contributed equally to this work.
    • ,
  • Biao Liang

      Affiliations

    • Department of Gastroenterology and Hepatology, the Second People's Hospital of Guangdong Province, Guangdong, Guangzhou, China
    • ,
  • Xiaochun Shu

      Affiliations

    • Department of Endocrinology, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong, Zhuhai, China
    • ,
  • Danhong Xie

      Affiliations

    • Department of Endocrinology, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong, Zhuhai, China

Received 20 May 2009 ,Accepted 2 July 2009.

References 

  1. Adams LA, Lymp JF, St Sauver J, et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121
  2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112
  3. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994;20:1442–1449
  4. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52
  5. Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care. 2003;26:3351–3352
  6. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218
  7. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307
  8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231
  9. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis. 2004;8:501–519
  10. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care. 2008;31:562–568
  11. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262–265
  12. Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr. 1999;18:353–358
  13. Marchesini G, Moscatiello S, Di Domizio S, et al. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74–S80
  14. Marchesini G, Marzocchi R, Agostini F, et al. Non-alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–427
  15. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–240
  16. Ioannou GN, Weiss NS, Boyko EJ, et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43:1145–1151
  17. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10 year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391–396
  18. Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. Diagnostic criteria of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2006;14:161–163
  19. Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. 2006;23:403–409
  20. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541–3546
  21. Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004;27:2689–2694
  22. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173:309–314
  23. Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–169
  24. Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004;53:2855–2860
  25. Hanley AJ, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–3147
  26. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase and the 6 year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med. 2007;24:430–435
  27. Adibi P, Sadeghi M, Mahsa M, et al. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int. 2007;27:895–900
  28. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med. 2006;6:19–25

PII: S0188-4409(09)00135-0

doi: 10.1016/j.arcmed.2009.07.009

Archives of Medical Research
Volume 40, Issue 7 , Pages 571-575 , October 2009

Article Tools